Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.

"M.C. received support from a grant from ViiV Healthcare and payment for lectures, including service on speakers’ bureaus, from Abbott Laboratories. K.C., H.P.G., S.L.F., M.B.W., N.G., L.L.R., Y.L., T.P. and J.S. are employees of GlaxoSmithKline. The authors have no other funding or conflicts of interest to disclose"

"This study is sponsored and funded by ViiV Healthcare; GlaxoSmithKline is responsible for implementing and managing all aspects of this study. M.C. received support from a grant from ViiV Healthcare and payment for lectures, including service on speakers’ bureaus, from Abbott Laboratories. K.C., H.P.G., S.L.F., M.B.W., N.G., L.L.R., Y.L., T.P. and J.S. are employees of GlaxoSmithKline. The authors have no other funding or conflicts of interest to disclose"